Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

Rhea-AI Summary

Cyclacel Pharmaceuticals plans to present at the Biotech Showcase and host meetings at a Corporate Access Event from January 9-11, 2023, in San Francisco. Spiro Rombotis, CEO, and Paul McBarron, EVP, will discuss the company's clinical advancements and goals. The Biotech Showcase presentation is on January 10 at 9:30 am PT at Hilton San Francisco Union Square. Cyclacel focuses on cancer therapies, particularly fadraciclib and CYC140, addressing solid tumors and hematological malignancies. For more details, visit www.cyclacel.com.

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023 in San Francisco, California.

Biotech Showcase:
Spiro Rombotis, President and Chief Executive Officer, and Paul McBarron, EVP, Finance & COO, will provide an overview of the Company including clinical progress and expected milestones.

Date/Time: Tuesday January 10, 2023, at 9:30 am PT
Location: Hilton San Francisco Union Square in San Francisco; Yosemite A (Ballroom Level)
To schedule a meeting with management, investors can register on the Biotech Showcase website

LifeSci Partners Corporate Access Event:
Spiro Rombotis, President and Chief Executive Officer, and Paul McBarron, EVP, Finance & COO, will be hosting meetings with institutional investors.

Date/Time: Monday, January 9, 2023
Location: Beacon Grand Hotel, San Francisco
Please click here to register for the conference and schedule a meeting with management via the online system managed by LifeSci Partners.

About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com. 

Contacts

Company:	Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com
Investor Relations:	Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com

© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel^® are trademarks of Cyclacel Pharmaceuticals, Inc.

 

FAQ

When is Cyclacel presenting at the Biotech Showcase?

Cyclacel will present on January 10, 2023, at 9:30 am PT.

Where is the Biotech Showcase located?

The Biotech Showcase will be held at Hilton San Francisco Union Square.

What is the focus of Cyclacel Pharmaceuticals?

Cyclacel focuses on developing innovative cancer medicines, particularly for solid tumors and hematological malignancies.

Who will represent Cyclacel at the events?

Spiro Rombotis, CEO, and Paul McBarron, EVP, will represent Cyclacel.

How can investors meet with Cyclacel's management?

Investors can register on the Biotech Showcase website to schedule meetings.

What drugs are Cyclacel currently developing?

Cyclacel is developing fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor.

What are the dates for the Corporate Access Event?

The Corporate Access Event is on January 9, 2023.

What is the stock symbol for Cyclacel Pharmaceuticals?

The stock symbols are CYCC and CYCCP.